SEARCH

SEARCH BY CITATION

References

  • Ashford AR, Donev I, Tiwari RP & Garrett TJ (1988): Reversible ocular toxicity related to tamoxifen therapy. Cancer 61: 3335.
  • Beck M & Mills PV (1979): Ocular assessment of patients treated with tamoxifen. Cancer Treat Rep 63: 18331834.
  • Bentley CR, Davies G & Aclimandos WA (1992): Tamoxifen retinopathy: a rare but serious complication. Br Med J 304: 495496.
  • Bernardo G, Redaelli C, Plastina M, Bernardo A, Strada MR, Bottero G & Betta PG (1994): Longterm adjuvant therapy with tamoxifen (TAM). An evaluation of the ocular toxicity. Proc ASCO 13: 106.
  • Chang T, Gonder JR & Ventresca MR (1992): Low dose tamoxifen retinopathy. Can J Ophthalmol 27: 148149.
  • Chern S & Danis RP (1993): Retinopathy associated with low dose tamoxifen. Am J Ophthalmol 116: 372373.
  • Costa RH, Dhooge MR, Wing FV & De Rouck AF (1990): Tamoxifen retinopathy. A Case Report. Bull Soc Belge Ophthalmol 238: 161168.
  • De Jong-Busnac M (1989): Oogheelkundige complicaties van tamoxifen in lage dosering bij de behandeling van mammacarcinoom. Ned Tijdschr Geneeskd 133: 514516.
  • Fisher B, Costantino JP, Wickerham DL et al. (1998): Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study. J Nat Cancer Inst 90: 13711388.
  • Francois J & De Laey JJ (1977): Biettische kristalline Fundusdystrophie. Klin Monatsbl Augenheilkd 8: 105110.
  • Gerner EW (1989): Ocular toxicity of tamoxifen. Ann Ophthalmol 21: 420423.
  • Gorin MB, Day R, Costantino JP et al. (1998): Longterm tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 125: 493501.
  • Griffiths MF (1987): Tamoxifen retinopathy at low dosage. Am J Ophthalmol 104: 185186.
  • Harnois C, Samson J & Malenfant M (1989): Canthaxanthin retinopathy. Anatomic and functional reversibility. Arch Ophthalmol 107: 538540.
  • Heier JS, Dragoo RA, Enzenauer RW & Waterhouse WJ (1994): Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 117: 772775.
  • Holli K, Valavaara R, Blanco G, Kataja V, Hietanen P, Flander M, Pukkala E & Joensuu H (2000): Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. J Clin Oncol 18: 34873494.
  • International Agency for Research on Cancer (IARC) (1996): IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 66. Some Pharmaceutical Drugs. Lyon: International Agency for Research on Cancer.
  • ICI Pharmaceuticals Group (1990): Data presented at the Food and Drug Administration Oncology Drug Advisory Committee Meeting. Bethesda, Maryland. June 29 1990.
  • Jagell S, Polland W & Sandgren O (1980): Specific changes in the fundus typical for the Sjögren–Larsson syndrome. An ophthalmological study of 35 patients. Acta Ophthalmol Scand 58: 321330.
  • Kaiser-Kupfer MI, Caruso RC & Minkler DS (1986): Longterm ocular manifestations in nephropathic cystinosis. Arch Ophthalmol 104: 706711.
  • Kaiser-Kupfer MI, Kupfer C & Rodrigues MM (1981): Tamoxifen retinopathy. A clinicopathologic report. Ophthalmology 88: 8993.
  • Kaiser-Kupfer MI & Lippman ME (1978): Tamoxifen retinopathy. Cancer Treat Rep 62: 315320.
  • Karlsson S, Hirsimäki Y, Mäntylä E et al. (1996): A 2-year dietary carcinogenicity study of the anti-oestrogen toremifene in Sprague-Dawley rats. Drug Chem Toxicol 19: 245266.
  • Klein BE, Klein R & Lee KE (2002): Incidence of age-related cataract over a 10-year interval. The Beaver Dam Eye Study. Ophthalmology 109: 20522057.
  • Kramer BS, Brawley OW, Nayfield S, Johnson K, Greenwald P & Ford LG (1993): NCI studies in primary prevention of breast and prostate cancer. Cancer Res Ther Control 3: 203211.
  • Lazzaroni F, Scorolli L, Pizzoleo CF, Savini G, De Nigris A, Giosa F & Meduri RA (1998): Tamoxifen retinopathy: does it really exist? Graefes Arch Clin Exp Ophthalmol 236: 669673.
  • Longstaff S, Sigurdsson H, O'Keeffe M, Ogston S & Preece P (1989): A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol 25: 18051808.
  • Lullmann H & Lullmann-Rauch R (1981): Tamoxifen-induced generalized lipidosis in rats subchronically treated with high doses. Toxicol Appl Pharmacol 61: 138146.
  • Mäenpää J, Holli K & Pasanen T (2000): Toremifene: where do we stand? Eur J Cancer 36: 6162.
  • Mannerström M, Mäenpää H, Toimela T, Salminen L & Tähti H (2001): The phagocytosis of rod outer segments is inhibited by selected drugs in retinal pigment epithelial cell cultures. Pharmacol Toxicol 88: 2733.
  • McKeown CA, Swartz M, Blom J & Maggiano JM (1981): Tamoxifen retinopathy. Br J Ophthalmol 65: 177179.
  • McLane NJ & Carroll DM (1986): Ocular manifestations of drug abuse. Surv Ophthalmol 30: 298313.
  • Nayfield SG & Gorin MB (1996): Tamoxifen-associated eye disease: a review. J Clin Oncol 14: 10181026.
  • Noureddin B, Seoud M, Bashshur Z, Salem Z, Shamseddin A & Khalil A (1999): Ocular toxicity in low dose tamoxifen: a prospective study. Eye 13: 729733.
  • Paganini-Hill A & Clark LJ (2000): Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 60: 167172.
  • Pappas P, Stephanou P, Sotiropoulou M, Murphy C, Salminen L & Marselos M (1999): Effects of tamoxifen and toremifene on ALDH1 and ALDH3 in human retinal pigment epithelial cells and rat liver. Adv Exp Med Biol 463: 151158.
  • Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J & Petroutsos G (1992): Clear evidence that longterm, low dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 69: 29612964.
  • Polak BC & Hogewind BL (1977): Macular lesions in Alport's disease. Am J Ophthalmol 84: 532535.
  • Pugesgaard T & Von Eyben FE (1986): Bilateral optic neuritis evolved during tamoxifen treatment. Cancer 58: 383386.
  • Sekhar GC & Nagarajan R (1995): Ocular toxicity of tamoxifen. Indian J Ophthalmol 43: 2326.
  • Small KW, Letson R & Scheinman J (1990): Ocular findings in primary hyperoxaluria. Arch Ophthalmol 108: 8993.
  • Smith NF, Ripps H & Goodman G (1959): Retinitis punctata albescens. A functional and diagnostic evaluation. Arch Ophthalmol 61: 93101.
  • Therssen R, Jansen E, Leys A, Rutten J & Meyskens J (1995): Screening for tamoxifen ocular toxicity: a prospective study. Eur J Ophthalmol 5: 230234.
  • Toimela T, Salminen L & Tähti H (1998): Effects of tamoxifen, toremifene and chloroquine on the lysosomal enzymes in cultured retinal pigment epithelial cells. Pharmacol Toxicol 83: 246251.
  • Vinding T & Nielsen NV (1983): Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophthalmol Scand 61: 4550.
  • Werblin TP, Hirst LW & Stark WJ (1981): Prevalence of map-dot-fingerprint changes in the cornea. Br J Ophthalmol 65: 401409.
  • Yanyali AC, Freund KB, Sorenson JA, Slakter JS & Wheatley HM (2001): Tamoxifen retinopathy in a male patient. Am J Ophthalmol 131: 386387.